

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-H-053**

Please note that we have provided this information for the period June to August 2022.

You asked:

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Abemaciclib patients – total of 8 patients on all combinations
Abemaciclib + Fulvestrant	
Alpelisib + Fulvestrant	0
Atezolizumab	0
Bevacizumab	0
Eribulin as a single agent or in combination	6
Everolimus + Exemestane	We are unable to split Everolimus patients – total of <5* patients on all combinations
Fulvestrant as a single agent	
Gemcitabine + paclitaxel	<5*
Herceptin (Trastuzumab) + paclitaxel	<5*
Herceptin (Trastuzumab) as a single agent	<5*
Lapatinib	0
Neratinib	0
Olaparib	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Palbociclib patients – total of 34 patients on all combinations
Palbociclib + Fulvestrant	
Pertuzumab (Perjeta) + trastuzumab + docetaxel	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Ribociclib patients – total of 6 patients on all combinations
Ribociclib + Fulvestrant	
Talazoparib (Talzenna)	0
Trastuzumab emtansine	6



Any other active systemic anti-cancer therapy	48
---	----

2. For the above patients, how many of these received their first ever dose for each product line?

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Abemaciclib + Fulvestrant	0
Alpelisib + Fulvestrant	0
Atezolizumab	0
Bevacizumab	0
Eribulin as a single agent or in combination	5
Everolimus + Exemestane	0
Fulvestrant as a single agent	<5*
Gemcitabine + paclitaxel	<5*
Herceptin (Trastuzumab) + paclitaxel	0
Herceptin (Trastuzumab) as a single agent	0
Lapatinib	0
Neratinib	0
Olaparib	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Palbociclib patients – total of <5* patients on all combinations
Palbociclib + Fulvestrant	
Pertuzumab (Perjeta) + trastuzumab + docetaxel	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Ribociclib patients – total of <5* patients on all combinations
Ribociclib + Fulvestrant	
Talazoparib (Talzenna)	0
Trastuzumab emtansine	<5*
Any other active systemic anti-cancer therapy	26

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

